Day One Biopharmaceuticals is a clinical-stage biotechnology company focused on developing therapies for patients with cancer. The company's lead product candidate, DAY101, is a potent and selective oral inhibitor of FGFR3, a driver of bladder cancer. Day One is also developing a pipeline of other oncology drug candidates, including DAY102, a selective oral inhibitor of FGFR2b, and DAY301, a selective oral inhibitor of SHP2. The company is headquartered in South San Francisco, California.